Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain EGRX message board posts where the ticker symbol EGRX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest EGRX SEC Filings

Filings Format Description Filing Date File/Film Number
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000827871-17-000010 (34 Act)  Size: 5 MB
2017-11-08 001-36306
171187411
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-17-066788 (34 Act)  Size: 443 KB
2017-11-08 001-36306
171185025
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-17-064380 (34 Act)  Size: 42 KB
2017-10-27 001-36306
171160006
8-K  Documents Current report, items 1.01, 7.01, and 9.01
Acc-no: 0001104659-17-058905 (34 Act)  Size: 2 MB
2017-09-26 001-36306
171102750
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-17-057982 (34 Act)  Size: 47 KB
2017-09-20 001-36306
171093264
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001104659-17-056889 (34 Act)  Size: 2 MB
2017-09-13 001-36306
171082237
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000905718-17-000811 (34 Act)  Size: 63 KB
2017-08-24 005-88022
171049994
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-049317 Size: 5 KB
2017-08-16
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-048604 Size: 12 KB
2017-08-11
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000827871-17-000007 (34 Act)  Size: 5 MB
2017-08-09 001-36306
171018492
More EGRX SEC Filings


Related news from
Sat, 16 Dec 2017
00:13:00 +0000
Cramer's lightning round: Buy Cisco when it goes below $3...
Jim Cramer shared his take on callers' favorite stocks at lightning speed, including one high-profile tech name.
Thu, 07 Dec 2017
11:50:00 +0000
Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant
Eagle Pharmaceuticals, Inc. today announced that it has begun dosing subjects in its pivotal study for the Company’s fulvestrant formulation intended as a monotherapy treatment of hormone receptor -positive, human epidermal growth factor receptor 2 -negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal ...
Mon, 27 Nov 2017
13:05:58 +0000
See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Short interest is extremely high for EGRX with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting EGRX. ETFs that hold EGRX had net inflows of $2.83 billion over the last one-month.
Mon, 20 Nov 2017
21:30:00 +0000
Eagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare Conference
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
Fri, 17 Nov 2017
02:01:00 +0000
Barron's After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges
U.S stocks rallied after the House of Representatives passed tax-reform legislation on Thursday with the Dow Jones Industrial Average gaining 187 points. Early signs are that the positive sentiment is ...
Fri, 17 Nov 2017
01:36:00 +0000
Edited Transcript of EGRX earnings conference call or presentation 8-Nov-17 1:30pm GMT
Q3 2017 Eagle Pharmaceuticals Inc Earnings Call
Fri, 10 Nov 2017
18:10:49 +0000
Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : November 10, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Eagle Pharmaceuticals, Inc. a score of 75. Our analysis is based on comparing Eagle Pharmaceuticals, Inc. with the following peers – Madrigal Pharmaceuticals, Inc., Johnson & Johnson, GlaxoSmithKline plc Sponsored ADR, Medicines Company, Novartis AG Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Bristol-Myers Squibb Company, Amgen ... Read more <b>(Read more...)</b>
Thu, 09 Nov 2017
12:21:26 +0000
Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : November 9, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Eagle Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more <b>(Read more...)</b>
Wed, 08 Nov 2017
15:44:48 +0000
Eagle Pharmaceuticals posts 3Q profit
On a per-share basis, the Woodcliff Lake, New Jersey-based company said it had profit of 98 cents. Earnings, adjusted for one-time gains and costs, came to $1.22 per share. The specialty pharmaceutical ...
Wed, 08 Nov 2017
11:50:00 +0000
Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results
Eagle Pharmaceuticals, Inc. today announced its financial results for the three- and nine-months ended September 30, 2017. Highlights of a
Wed, 08 Nov 2017
11:10:00 +0000
Eagle Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 8:30 AM ...
Tue, 07 Nov 2017
21:30:00 +0000
Eagle Pharmaceuticals, Inc. to Present at Jefferies 2017 London Healthcare Conference
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, will present at the Jefferies 2017 London Healthca
Mon, 30 Oct 2017
20:30:00 +0000
Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2017 third quarter financial results on Wednesday, November 8, 2017, before the market opens.
Fri, 27 Oct 2017
20:44:45 +0000
Eagle Pharma gets tentative FDA approval for Lilly's Alimta version
Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta. The company expects to capture about 25 percent or a third of the market, Chief Executive Scott Tarriff said in an interview. A final approval - which would allow Eagle Pharma to sell the drug in the United States - is subject to resolution of a patent litigation with Lilly.
Fri, 27 Oct 2017
19:14:53 +0000
FDA tentatively approves Eagle Pharma's cancer drug
Eagle Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration tentatively approved its injectable drug to treat a most common type of lung cancer and a cancer of mesothelial tissue. ...
Fri, 27 Oct 2017
19:02:00 +0000
Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute
Eagle Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration has granted tentative approval for the Company’s PEMFEXY™, a pemetrexed injection ready-to-dilute formulation for locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin; locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not ...
Tue, 24 Oct 2017
13:37:21 +0000
ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 24, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Eagle Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to EGRX-US. Comparing the performance and risk of Eagle Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Tue, 17 Oct 2017
11:33:00 +0000
Eagle Pharmaceuticals Announces New Patent for RYANODEX
Eagle Pharmaceuticals, Inc. today announced that the Company has been issued a new patent related to its RYANODEX® formulation by the United States Patent and Trademark Office .
Sun, 15 Oct 2017
16:00:00 +0000
3 Biotech Values in a Fully Valued Market
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF has been a blessing to me and my family. Even if you are not a big contributor, the information is there for you to read. It is amazing that the fine members of VF will openly help and provide ideas to enhance each others investing." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards